Table of Contents
ISRN Oncology
Volume 2011, Article ID 403098, 13 pages
http://dx.doi.org/10.5402/2011/403098
Review Article

Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective

1Département d’Oncologie, Institut Curie, 75005 Paris, France
2Centrum Gynaecologische Oncologie Amsterdam, AMC, NKI-AVL, and VUmc, 1007 MB, Amsterdam, The Netherlands
3Department of Gynacologic Oncology & Gynaecology, University Hospital of Essen, Henricistrasse 92, 45136 Essen, Germany

Received 4 April 2011; Accepted 30 April 2011

Academic Editors: A. Goussia, H.-W. Lo, and S. Mohanam

Copyright © 2011 Susy M. E. Scholl et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, F. Bray, and H. R. Shin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer.
  2. F. Kamangar, G. M. Dores, and W. F. Anderson, “Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world,” Journal of Clinical Oncology, vol. 24, no. 14, pp. 2137–2150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Arbyn, J. Antoine, M. Mägi et al., “Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania,” International Journal of Cancer, vol. 128, no. 8, pp. 1899–1907, 2011. View at Publisher · View at Google Scholar
  4. M. Arbyn, A. O. Raifu, E. Weiderpass, F. Bray, and A. Anttila, “Trends of cervical cancer mortality in the member states of the European Union,” European Journal of Cancer, vol. 45, no. 15, pp. 2640–2648, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. P. G. Rose, B. N. Bundy, E. B. Watkins et al., “Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer,” New England Journal of Medicine, vol. 340, no. 15, pp. 1144–1153, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Uzan, E. Vincens, C. Balleyguier et al., “Outcome of patients with incomplete resection after surgery for stage IB2/II cervical carcinoma with chemoradiation therapy,” International Journal of Gynecological Cancer, vol. 20, no. 3, pp. 379–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. P. E. Colombo, M. M. Bertrand, M. Gutowski et al., “Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: surgical morbidity and oncological results,” Gynecologic Oncology, vol. 114, no. 3, pp. 404–409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. H. Moore, “Combined chemotherapy and radiation therapy for cervical cancer,” Journal of the National Comprehensive Cancer Network, vol. 2, no. 6, pp. 631–635, 2004. View at Google Scholar · View at Scopus
  9. I. Fuchs, N. Vorsteher, H. Bühler et al., “The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma,” Anticancer Research, vol. 27, no. 2, pp. 959–963, 2007. View at Google Scholar · View at Scopus
  10. M. G. Noordhuis, J. J. H. Eijsink, K. A. Ten Hoor et al., “Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (Chemo)radiation and survival in cervical cancer,” Clinical Cancer Research, vol. 15, no. 23, pp. 7389–7397, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Zhu, W. T. Y. Loo, and W. C. C. Louis, “PTEN and VEGF: possible predictors for sentinel lymph node micro-metastasis in breast cancer,” Biomedicine and Pharmacotherapy, vol. 61, no. 9, pp. 558–561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Tian, K. J. Nan, S. H. Wang et al., “PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells,” Carcinogenesis, vol. 31, no. 7, pp. 1211–1219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. W. Qiu, D. G. Lin, J. Q. Wang, C. Y. Li, and G. Z. Deng, “Expression and significance of PTEN and VEGF in canine mammary gland tumours,” Veterinary Research Communications, vol. 32, no. 6, pp. 463–472, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Ma, H. Sawai, N. Ochi et al., “PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells,” Molecular and Cellular Biochemistry, vol. 331, no. 1-2, pp. 161–171, 2009. View at Google Scholar · View at Scopus
  15. E. Toussaint-Smith, D. B. Donner, and A. Roman, “Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors,” Oncogene, vol. 23, no. 17, pp. 2988–2995, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. O. López-Ocejo, A. Viloria-Petit, M. Bequet-Romero, D. Mukhopadhyay, J. Rak, and R. S. Kerbel, “Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner,” Oncogene, vol. 19, no. 40, pp. 4611–4620, 2000. View at Google Scholar · View at Scopus
  17. D. L. Jones, D. A. Thompson, and K. Münger, “Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis,” Virology, vol. 239, no. 1, pp. 97–107, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Buitrago-Perez, G. Garaulet, A. Vazquez-Carballo, J. M. Paramio, and R. García-Escudero, “Molecular signature of HPV-induced carcinogenesis: pRb, p53 and gene expression profiling,” Current Genomics, vol. 10, no. 1, pp. 26–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. A. H. N. Hopman, W. Theelen, P. P. H. Hommelberg et al., “Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer,” Journal of Pathology, vol. 210, no. 4, pp. 412–419, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. H. zur Hausen, “Papillomaviruses in the causation of human cancers—a brief historical account,” Virology, vol. 384, no. 2, pp. 260–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. H. zur Hausen, “The search for infectious causes of human cancers: where and why,” Virology, vol. 392, no. 1, pp. 1–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Münger, A. Baldwin, K. M. Edwards et al., “Mechanisms of human papillomavirus-induced oncogenesis,” Journal of Virology, vol. 78, no. 21, pp. 11451–11460, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Eichten, D. S. Rud, M. Grace, S. O. Piboonniyom, V. Zacny, and K. Münger, “Molecular pathways executing the “trophic sentinel” response in HPV-16 E7-expressing normal human diploid fibroblasts upon growth factor deprivation,” Virology, vol. 319, no. 1, pp. 81–93, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Saxena, S. Singh, M. P. S. Negi et al., “Expression profiling of G2/M phase regulatory proteins in normal, premalignant and malignant uterine cervix and their correlation with survival of patients,” Journal of Cancer Research and Therapeutics, vol. 6, no. 2, pp. 167–171, 2010. View at Publisher · View at Google Scholar
  25. E. V. Khokhlova, A. N. Shkoporov, N. N. Volodin, B. A. Efimov, K. A. Pavlov, and L. I. Kafarskaia, “Relationship between suppression of E6 and E7 virus oncogenes and expression of apoptosis and cell cycle genes in cervical cancer culture,” Bulletin of Experimental Biology and Medicine, vol. 149, no. 1, pp. 73–77, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Strebhardt, “Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy,” Nature Reviews Drug Discovery, vol. 9, no. 8, pp. 643–660, 2010. View at Publisher · View at Google Scholar
  27. R. A. Donnianni, M. Ferrari, F. Lazzaro et al., “Elevated levels of the polo kinase Cdc5 override the Mec1/ATR checkpoint in budding yeast by acting at different steps of the signaling pathway,” PLoS Genetics, vol. 6, no. 1, Article ID e1000763, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Chopra, G. Sethi, S. G. Dastidar, and A. Ray, “Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics,” Expert Opinion on Investigational Drugs, vol. 19, no. 1, pp. 27–43, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Matloubian, R. J. Concepcion, and R. Ahmed, “CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection,” Journal of Virology, vol. 68, no. 12, pp. 8056–8063, 1994. View at Google Scholar · View at Scopus
  30. H. Zur Hausen, “Papillomavirus infections—a major cause of human cancers,” Biochimica et Biophysica Acta, vol. 1288, no. 2, pp. F55–F78, 1996. View at Publisher · View at Google Scholar · View at Scopus
  31. E. M. L. Evans, S. Man, A. S. Evans, and L. K. Borysiewicz, “Infiltration of cervical cancer tissue with Human Papillomavirus- specific cytotoxic T-Lymphocytes,” Cancer Research, vol. 57, no. 14, pp. 2943–2950, 1997. View at Google Scholar · View at Scopus
  32. S. J. Piersma, M. J. P. Welters, and S. H. van der Burg, “Tumor-specific regulatory T cells in cancer patients,” Human Immunology, vol. 69, no. 4-5, pp. 241–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. S. J. Piersma, E. S. Jordanova, M. I. E. Van Poelgeest et al., “High number of intraepithelial CD8 tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer,” Cancer Research, vol. 67, no. 1, pp. 354–361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. A. De Jong, M. I. E. Van Poelgeest, J. M. Van Der Hulst et al., “Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6,” Cancer Research, vol. 64, no. 15, pp. 5449–5455, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. G. G. Kenter, M. J. P. Welters, A. R. P. M. Valentijn et al., “Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity,” Clinical Cancer Research, vol. 14, no. 1, pp. 169–177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. J.-L. Brun, V. Dalstein, J. Leveque et al., “Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy,” American Journal of Obstetrics and Gynecology, vol. 204, no. 2, pp. 169.e1–169.e8, 2011. View at Publisher · View at Google Scholar
  37. J. Loeffler-Ragg, I. Schwentner, G. M. Sprinzl, and H. Zwierzina, “EGFR inhibition as a therapy for head and neck squamous cell carcinoma,” Expert Opinion on Investigational Drugs, vol. 17, no. 10, pp. 1517–1531, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. J. B. Vermorken, R. Mesia, F. Rivera et al., “Platinum-based chemotherapy plus cetuximab in head and neck cancer,” New England Journal of Medicine, vol. 359, no. 11, pp. 1116–1127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Mitsudomi and Y. Yatabe, “Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer,” FEBS Journal, vol. 277, no. 2, pp. 301–308, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Jeuken, A. Sijben, C. Alenda et al., “Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics,” Brain Pathology, vol. 19, no. 4, pp. 661–671, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. A. Weppler, Y. Li, L. Dubois et al., “Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance,” Radiotherapy and Oncology, vol. 83, no. 3, pp. 333–339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Pohl, W. Zhang, Y. Ning, P. C. Manegold, G. Lurje, and H.-J. Lenz, “Targeting metastatic colorectal cancer in 2008: a long way from 5-FU,” Oncology, vol. 22, no. 4, pp. 456–462, 2008. View at Google Scholar
  44. F. Walker, S. Kermorgant, E. Daraï et al., “Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus,” Clinical Cancer Research, vol. 9, no. 1 I, pp. 273–284, 2003. View at Google Scholar · View at Scopus
  45. M.-L. Serrano, M. Sánchez-Gómez, M.-M. Bravo, S. Yakar, and D. Leroith, “Differential expression of IGF-I and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines,” Hormone and Metabolic Research, vol. 40, pp. 661–667, 2008. View at Google Scholar
  46. J. M. Balko, A. Potti, C. Saunders, A. Stromberg, E. B. Haura, and E. P. Black, “Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors,” BMC Genomics, vol. 7, article 289, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. H. W. Lo, “Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications,” Discovery Medicine, vol. 10, pp. 44–51, 2010. View at Google Scholar
  48. C. Li, M. Iida, E. F. Dunn, A. J. Ghia, and D. L. Wheeler, “Nuclear EGFR contributes to acquired resistance to cetuximab,” Oncogene, vol. 28, no. 43, pp. 3801–3813, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Dittmann, C. Mayer, and H. P. Rodemann, “Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity,” Radiotherapy and Oncology, vol. 76, no. 2, pp. 157–161, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. H. P. Kim, Y. K. Yoon, J. W. Kim et al., “Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2,” PLoS ONE, vol. 4, no. 6, Article ID e5933, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. K. H. Dittmann, C. Mayer, P. A. Ohneseit et al., “Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism,” International Journal of Radiation Oncology Biology Physics, vol. 70, no. 1, pp. 203–212, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. H. W. Lo, S. C. Hsu, M. Ali-Seyed et al., “Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway,” Cancer Cell, vol. 7, no. 6, pp. 575–589, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Y. Hung, J. T. Tseng, Y. C. Lee et al., “Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression,” Nucleic Acids Research, vol. 36, no. 13, pp. 4337–4351, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. N. Kang, J. H. Zhang, F. Qiu, S. I. Tashiro, S. Onodera, and T. Ikejima, “Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways,” Cancer Letters, vol. 294, no. 2, pp. 147–158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Oliveras-Ferraros, A. M. Vall-Llovera, D. C. Salip et al., “Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells,” Investigational New Drugs, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21161326.
  56. K. Subbaramaiah and A. J. Dannenberg, “Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange,” Cancer Research, vol. 67, no. 8, pp. 3976–3985, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. R. S. Heist and D. Christiani, “EGFR-targeted therapies in lung cancer: predictors of response and toxicity,” Pharmacogenomics, vol. 10, no. 1, pp. 59–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. Ł. Kruszyna .L, M. Lianeri, A. Roszak, and P. P. Jagodziński, “HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma,” Clinical Biochemistry, vol. 43, no. 6, pp. 545–548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. B. J. Monk, L. M. Lopez, J. J. Zarba et al., “Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer,” Journal of Clinical Oncology, vol. 28, no. 22, pp. 3562–3569, 2010. View at Publisher · View at Google Scholar
  60. J. Tol, M. Koopman, A. Cats et al., “Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer,” New England Journal of Medicine, vol. 360, no. 6, pp. 563–572, 2009. View at Google Scholar · View at Scopus
  61. M. J. P. Welters, G. G. Kenter, S. J. Piersma et al., “Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine,” Clinical Cancer Research, vol. 14, no. 1, pp. 178–187, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. S. C. Fausch, L. M. Fahey, D. M. Da Silva, and W. M. Kast, “Human papillomavirus can escape immune recognition through langerhans cell phosphoinositide 3-kinase activation,” Journal of Immunology, vol. 174, no. 11, pp. 7172–7178, 2005. View at Google Scholar · View at Scopus
  63. G. G. Kenter, M. J. P. Welters, A. R. P. M. Valentijn et al., “Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia,” New England Journal of Medicine, vol. 361, no. 19, pp. 1838–1847, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. A. H. Klopp, A. Jhingran, L. Ramdas et al., “Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome,” International Journal of Radiation Oncology Biology Physics, vol. 71, no. 1, pp. 226–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. C. R. Wilson, S. E. Davidson, G. P. Margison, S. P. Jackson, J. H. Hendry, and C. M. L. West, “Expression of Ku70 correlates with survival in carcinoma of the cervix,” British Journal of Cancer, vol. 83, no. 12, pp. 1702–1706, 2000. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Harima, S. Sawada, Y. Miyazaki et al., “Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival,” American Journal of Clinical Oncology, vol. 26, pp. e80–e85, 2003. View at Google Scholar
  67. X. Yue, F. Lan, W. Yang et al., “Interruption of β-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells,” Brain Research, vol. 1366, pp. 27–37, 2010. View at Publisher · View at Google Scholar
  68. T. Hu and C. Li, “Convergence between Wnt-beta-catenin and EGFR signaling in cancer,” Molecular Cancer, vol. 9, article 236, 2010. View at Google Scholar
  69. T. Schlange, Y. Matsuda, S. Lienhard, A. Huber, and N. E. Hynes, “Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation,” Breast Cancer Research, vol. 9, no. 5, article R63, 2007. View at Google Scholar · View at Scopus
  70. Y. J. Zhou, Y. X. Xiong, X. T. Wu et al., “Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer,” World Journal of Gastroenterology, vol. 10, no. 21, pp. 3225–3229, 2004. View at Google Scholar · View at Scopus
  71. B. H. Jiang and L. Z. Liu, “Chapter 2 PI3K/PTEN signaling in angiogenesis and tumorigenesis,” Advances in Cancer Research, vol. 102, pp. 19–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Chen, L. Mei, L. Zhou et al., “PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts,” Journal of Neuro-Oncology, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2118847.
  73. S. E. Wang, B. Xiang, M. Guix et al., “Transforming growth factor β engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab,” Molecular and Cellular Biology, vol. 28, no. 18, pp. 5605–5620, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Mimeault and S. K. Batra, “Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies,” Pharmacological Reviews, vol. 62, no. 3, pp. 497–524, 2010. View at Publisher · View at Google Scholar
  75. M. F. Bijlsma, A. P. Groot, J. P. Oduro et al., “Hypoxia induces a hedgehog response mediated by HIF-1α,” Journal of Cellular and Molecular Medicine, vol. 13, no. 8 B, pp. 2053–2060, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. E. E. Cohen, D. W. Davis, T. G. Karrison et al., “Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study,” The Lancet Oncology, vol. 10, no. 3, pp. 247–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. M. T. McCabe, D. R. Powell, W. Zhou, and P. M. Vertino, “Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells,” Cancer Genetics and Cytogenetics, vol. 197, no. 2, pp. 130–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. L. S. Faried, A. Faried, T. Kanuma et al., “Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: a potential biomarker and molecular target therapy,” Molecular Carcinogenesis, vol. 47, no. 6, pp. 446–457, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. E. Van Cutsem, H. Van De Velde, P. Karasek et al., “Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer,” Journal of Clinical Oncology, vol. 22, no. 8, pp. 1430–1438, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. T. A. Gatcliffe, K. S. Tewari, A. Shah et al., “A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer,” Gynecologic Oncology, vol. 112, no. 1, pp. 85–89, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. B. He, L. You, K. Uematsu et al., “A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells,” Neoplasia, vol. 6, no. 1, pp. 7–14, 2004. View at Google Scholar · View at Scopus
  82. L. You, B. He, K. Uematsu et al., “Inhibition of Wnt-1 signaling induces apoptosis in β -catenin-deficient mesothelioma cells,” Cancer Research, vol. 64, no. 10, pp. 3474–3478, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. L. You, B. He, Z. Xu et al., “An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth,” Cancer Research, vol. 64, no. 15, pp. 5385–5389, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. G. Steinbach, P. M. Lynch, R. K. S. Phillips et al., “The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis,” New England Journal of Medicine, vol. 342, no. 26, pp. 1946–1952, 2000. View at Publisher · View at Google Scholar · View at Scopus
  85. R. K. S. Phillips, M. H. Wallace, P. M. Lynch et al., “A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis familial adenomatous polyposis,” Gut, vol. 50, no. 6, pp. 857–860, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. E. M. J. Boon, J. J. Keller, T. A. M. Wormhoudt et al., “Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines,” British Journal of Cancer, vol. 90, no. 1, pp. 224–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Akhter, X. Chen, P. Bowrey, E. J. Bolton, and D. L. Morris, “Vitamin D analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model,” Diseases of the Colon and Rectum, vol. 40, no. 3, pp. 317–321, 1997. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Lepourcelet, Y. N. P. Chen, D. S. France et al., “Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex,” Cancer Cell, vol. 5, no. 1, pp. 91–102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Shan and J. J. Zheng, “Optimizing Dvl PDZ domain inhibitor by exploring chemical space,” Journal of Computer-Aided Molecular Design, vol. 23, no. 1, pp. 37–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. J. Shan, D. L. Shi, J. Wang, and J. Zheng, “Identification of a specific inhibitor of the dishevelled PDZ domain,” Biochemistry, vol. 44, no. 47, pp. 15495–15503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. A. N. Lukashev, C. Fuerer, M. J. Chen, P. Searle, and R. Iggo, “Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954,” Human Gene Therapy, vol. 16, no. 12, pp. 1473–1483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. P. L. Iversen, V. Arora, A. J. Acker, D. H. Mason, and G. R. Devi, “Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans,” Clinical Cancer Research, vol. 9, no. 7, pp. 2510–2519, 2003. View at Google Scholar · View at Scopus
  93. Z. Sangale, C. Prass, A. Carlson et al., “A robust immunohistochemical assay for detecting pten expression in human tumors,” Applied Immunohistochemistry and Molecular Morphology, vol. 19, no. 2, pp. 173–183, 2011. View at Publisher · View at Google Scholar
  94. T. Mitsudomi and Y. Yatabe, “Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer,” Cancer Science, vol. 98, no. 12, pp. 1817–1824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. J. H. Van Krieken, A. Jung, T. Kirchner et al., “KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program,” Virchows Archiv, vol. 453, no. 5, pp. 417–431, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. P. Laurent-Puig, A. Cayre, G. Manceau et al., “Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5924–5930, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. C. Printz, “BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery,” Cancer, vol. 116, no. 14, pp. 3307–3308, 2010. View at Publisher · View at Google Scholar
  99. R. C. Castellino and D. L. Durden, “Mechanisms of disease: the PI3K-Akt-PTEN signaling node—an intercept point for the control of angiogenesis in brain tumors,” Nature Clinical Practice Neurology, vol. 3, no. 12, pp. 682–693, 2007. View at Publisher · View at Google Scholar